|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
FridayECTRIMS Congress 2013: Oral MS drug Gilenya® shows up to 71% reduction in annualised relapse rates
ECTRIMS Congress 2013
Novartis showcases data from 13 abstracts on fingolimod The data being presented for fingolimod at ECTRIMS/ACTRIMS highlight the Novartis clinical trial program for sphingosine 1-phosphate receptor (S1PR) modulators. Fingolimod targets MS via effects on the immune system and new pre-clinical data to be presented at ECTRIMS/ACTRIMS supports an Read more » Labels: Ectrims 2013, Gilenya (Fingolimod), Novartis |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||